At a high level, BSWH`s value design, like that of many organizations, is the quality/cost ratio of the services provided and the access to those services. In this context of value, and especially in the field of pharmacotherapy, I think the concept of tailor-made care and coordination of the right patient with the right treatment becomes very important. Is there, for example, a patient who could benefit from a particular drug therapy that she does not receive? That would be a problem of under-utilization. Conversely, is a patient taking a medication that probably doesn`t help their condition or does they have risks that outweigh the potential benefits? It would be a problem of overcharging. Does a patient also have access to their prescribed medications and take them correctly? Each of these scenarios affects the relative value of drug therapy. When it comes to value-based contracts, he said, “The biggest risk we see across the country is that health organizations are moving too fast, if at all.” The results are measured on the basis of a comprehensive analysis of the medical and administrative data of the claims. Several metrics are analyzed, including: there is a growing interest in value-based contracts for improving public health management, where health systems and responsible care organizations (ACOS) take responsibility for patient populations, not just individual patients – and aim to add value to the broader continuum of care across inpatient and outpatient environments. . .